NCT00056238已完成2 期
A Phase II Pilot Study of the Safety, Tolerability and Pharmacokinetics of Cerebril™ in Patients With Lobar Hemorrhage Related to Cerebral Amyloid Angiopathy
Bellus Health Inc. - a GSK company9 个研究点 分布在 1 个国家目标入组 30 人开始时间: 2003年2月1日最近更新:
适应症
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 30
- 试验地点
- 9
研究概览
简要总结
The main objective of this study is to evaluate the safety, tolerability and pharmacokinetics of Cerebril™ in Cerebral Amyloid Angiopathy (CAA) patients who have had lobar cerebral hemorrhage.
详细描述
Hemorrhagic Stroke due to CAA represents approximately 7% of all strokes.
The current phase II clinical study investigates the safety, tolerability, pharmacokinetic and pharmacodynamic profiles of the drug candidate in patients who have suffered lobar hemorrhages. The initial phase of the study is also aimed at determining the optimal dosing regimens for subsequent drug candidate efficacy trials. The trial is also evaluating the appearance of new cerebral hemorrhages on gradient-echo MRI scans, the amyloid ß (Aß) protein levels in the plasma and cerebrospinal fluid and the neurological and cognitive functions.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double
入排标准
- 年龄范围
- 55 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients must be 55 years of age or older.
- •Males and females. Females must be of non-childbearing potential (i.e. surgically sterilized or at least one year post-menopausal).
- •Diagnosis of possible or probable CAA based on the Boston Criteria for Diagnosis of CAA-Related Hemorrhage.
- •Nonfatal lobar hemorrhage (defined as hemorrhage in the cerebral cortex and underlying white matter sparing the basal ganglia and thalamus) within previous five years diagnosed by CT or MRI scan.
- •Patient has no intent to donate blood for 4 weeks after completion of the study.
- •Signed informed consent.
排除标准
- •Other established causes of hemorrhage at the time of the index hemorrhage event. Exclusion causes include excessive anticoagulation (INR > 4.0), associated head trauma or ischemic stroke, CNS tumor, vascular malformation, vasculitis, and blood dyscrasia.
- •Patient with a clinically significant and uncontrolled cardiovascular, renal, hepatic, pulmonary, gastrointestinal, endocrine, metabolic, ophthalmologic, hematological condition or other significant medical disease.
- •Presence of any condition that could interfere with the interpretation of study results or compromise patient safety.
- •Debilitated neurological state or other known disease likely to result in early death.
- •Disability characterized by a modified Rankin score ≥
- •ALT, ALP, AST or total bilirubin ≥ 1.5 the upper limit of normal ranges.
- •Contraindications to MRI scan (e.g. cranial metallic implant, cardiac pacemaker, and severe claustrophobia).
- •Allergy and/or hypersensitivity to analgesic agents used for the lumbar puncture (for patients undergoing lumbar puncture only).
- •Allergy and/or hypersensitivity to any component of the study medication.
- •Use of an investigational drug within 30 days prior to Screening visit.
- •Use of warfarin or warfarin containing compounds and heparin or heparin containing compounds within 7 days prior to Baseline (Week 0) visit.
- •Diagnosis of cystatin C amyloid angiopathy.
- •Active alcohol and/or drug abuse.
- •Inability to provide legal consent
研究者
研究点 (9)
Loading locations...
相似试验
已完成
1 期
A Study to Investigate Sitravatinib as Monotherapy and in Combination With Tislelizumab in Participants With Unresectable Locally Advanced or Metastatic Hepatocellular Carcinoma or Gastric/Gastroesophageal Junction CancerCarcinoma, HepatocellularGastric/Gastroesophageal Junction CancerNCT03941873BeiGene111
终止
2 期
A Study of the Effects of CY6463 in Participants With Alzheimer's Disease With Vascular PathologyAlzheimer's Disease With Vascular PathologyNCT04798989Tisento Therapeutics12
招募中
1 期
Study of Oral and Long-Acting Injectable Cabotegravir and Rilpivirine in Virologically Suppressed Children Living With HIV-1, Two to Less Than 12 Years of AgeHIV-1-infectionNCT05660980National Institute of Allergy and Infectious Diseases (NIAID)90
进行中（未招募）
1 期
NTLA-2002 in Adults With Hereditary Angioedema (HAE)Hereditary AngioedemaNCT05120830Intellia Therapeutics37
已完成
1 期
Study of the Safety, Tolerability, Pharmacokinetic Characteristics of PA1010 in Healthy SubjectsChronic HBV InfectionNCT05468060Zhejiang Palo Alto Pharmaceuticals, Inc.80